$ News

Wedbush Upgrades Generation Bio to Outperform, Lowers Price Target to $5.5

Jefferies Downgrades Generation Bio to Hold, Lowers Price Target to $5

Trading Halt: Halt status updated at 5:25:00 PM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending

Here's Why We're A Bit Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Generation Bio Announces Third Quarter 2025 Financial Results

Generation Bio Q3 EPS $(0.82) Beats $(3.17) Estimate, Sales $1.594M Beat $660.000K Estimate

Generation Bio Announces CEO Transition

Generation Bio President, CEO Geoff McDonough To Become Board Chair, Effective Oct. 31; Yalonda Howze Names Interim CEO, President

Sector Update: Health Care Stocks Climb Late Afternoon

Generation Bio Shares Surge Following Restructuring Plans, Q2 Results

Needham Reiterates Buy on Generation Bio, Maintains $15 Price Target

12 Health Care Stocks Moving In Wednesday's Intraday Session

Wedbush Downgrades Generation Bio to Neutral, Maintains Price Target to $7

Generation Bio shares are trading higher after the company announced new data demonstrating that its cell-targeted lipid nanoparticle system selectively delivered siRNA to T cells in non-human primates.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates